Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
stocks
Insignia Financial: Revised deal still attractive
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,001.40 | 59.90 | 0.67% |
CAC 40 | 7,850.43 | 106.02 | 1.37% |
DAX 40 | 24,240.82 | 198.92 | 0.83% |
Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
FTSE 100 | 9,061.49 | 37.68 | 0.42% |
HKSE | 25,538.07 | 408.04 | 1.62% |
NASDAQ | 21,020.02 | 127.33 | 0.61% |
Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
NZX 50 Index | 12,809.98 | 15.92 | 0.12% |
S&P 500 | 6,358.91 | 49.29 | 0.78% |
S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
SSE Composite Index | 3,582.30 | 0.44 | 0.01% |